|
|
|
|
Patients Who Drink Too Much
(Click the title below to leave the MDLinx Network and go to the Journal's Website) American Family Physician, 07/02/09 Willenbring ML et al.- Excessive alcohol consumption is a leading cause of preventable morbidity and mortality,...
|
|
|
Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associate
FRAZER, Pa., June 30 /PRNewswire-FirstCall/ -- Cephalon, Inc.(Nasdaq: CEPH) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) requesting approval of NUVIGIL(R...
|
|
|
Quincy Bioscience Enrolling Fibromyalgia and Chronic Fatigue Sufferers in Pilot Study with Prevagen Profession
Chicago - (www.prevagentrials.com) People suffering from the symptoms of Fibromyalgia and Chronic Fatigue are invited to participate in an online pilot study.Quincy Bioscience launched the brain health product Prevagen in September of...
|
|
|
Cephalon Submits NUVIGIL Supplemental New Drug Application For The Treatment Of Excessive Sleepiness Associate
'This supplemental New Drug Application for a new use of NUVIGIL is another important milestone for Cephalon.We hope that this will be the first of many new indications for NUVIGIL over the next five years,' said Dr. Lesley Russell,...
|
|
|
Cephalon Submits NUVIGIL Supplemental New Drug Application For The Treatment Of Excessive Sleepiness Associate
Cephalon, Inc.(Nasdaq: CEPH) announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) requesting approval of NUVIGIL(R) (armodafinil) Tablets [C-IV] for the indication of...
|
|
|
Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associate
FRAZER, Pa., June 30 /PRNewswire-FirstCall/ -- Cephalon, Inc.( 'This supplemental New Drug Application for a new use of NUVIGIL is another important milestone for Cephalon. We hope that this will be the first of many new indications for...
|
|
|
Dads' Depression Linked to Later Infant Crying
TUESDAY, June 30 (HealthDay News) -- Symptoms of depression in soon-to-be fathers during pregnancy may be a risk factor for excessive infant crying, according to research published in the July issue of Pediatrics.Mijke P. van den Berg,...
|
|
|
Sad Dads May Lead to Crying Infants
TUESDAY, June 30 (HealthDay News) -- Don't automatically blame mom: A crying, colicky baby can be just as much the result of dad's state of mind, Dutch researchers report.Other studies have found that depression among mothers can be...
|
|
|
Sad dads may lead to crying infants
TUESDAY, June 30 (HealthDay News) -- Don't automatically blame mom: A crying, colicky baby can be just as much the result of dad's state of mind, Dutch researchers report.Other studies have found that depression among mothers can be...
|
|
|
Cephalon Submits SNDA For Nuvigil To FDA For Treatment Of Excessive Sleepiness Related To Jet Lag Disorder - U
AM ET RELATED NEWS TOP MARKET NEWS (RTTNews) - Biopharmaceutical company Cephalon, Inc.(CEPH: News ) said Tuesday that it submitted a supplemental New Drug Application or sNDA to the U.S. Food and Drug Administration or FDA for approval...
|
|
|
Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associate
'This supplemental New Drug Application for a new use of NUVIGIL is another important milestone for Cephalon.We hope that this will be the first of many new indications for NUVIGIL over the next five years,' said Dr. Lesley Russell The...
|
|
|
Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associate
Cephalon, Inc.(Nasdaq: CEPH) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) requesting approval of NUVIGIL(R) (armodafinil) Tablets [C-IV] for the...
|
|
|
Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associate
FRAZER, Pa., June 30 /PRNewswire-FirstCall/ -- Cephalon, Inc.(Nasdaq: CEPH) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) requesting approval of NUVIGIL(R...
|
|
|
Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associate
FRAZER, Pa., June 30 /PRNewswire-FirstCall/ -- Cephalon, Inc.(Nasdaq: CEPH) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) requesting approval of NUVIGIL(R...
|
|
|
Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associate
FRAZER, Pa., June 30 /PRNewswire-FirstCall/ -- Cephalon, Inc.(Nasdaq: CEPH) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) requesting approval of NUVIGIL(R...
|
|
|
Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associate
FRAZER, Pa., June 30 /PRNewswire-FirstCall/ -- Cephalon, Inc.(Nasdaq: CEPH) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) requesting approval of NUVIGIL(R...
|
|
|
Cephalon Submits SNDA To FDA For Nuvigil For Treatment Of Excessive Sleepiness Associated With Jet Lag Disorde
AM ET RELATED NEWS TOP MARKET NEWS (RTTNews) - Cephalon Inc.(CEPH: News ) announced that it has submitted a supplemental New Drug Application or sNDA to the U.S. Food and Drug Administration requesting approval of Nuvigil (armodafinil)...
|
|
|
Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associate
FRAZER, Pa., June 30 /PRNewswire-FirstCall/ -- Cephalon, Inc.(Nasdaq: CEPH) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) requesting approval of NUVIGIL(R...
|
|
|
Armodafinil Improves Excessive Sleepiness Associated With Treated Obstructive Sleep Apnoea in Patients With De
-- Armodafinil is generally well tolerated and significantly improves overall clinical conditions in patients with residual excessive sleepiness associated with continuous positive airway pressure (CPAP)-treated obstructive sleep apnoea (OSA...
|
|
|
Diabetes Is Significant Economic Burden For US Health-care System
Excess medical expenses and reduced productivity due to diabetes costs the U.S.economy more than $174 billion annually, a figure that could be reduced by lifestyle modifications and preventive care and by pay-for-performance incentives...
|
|
|
Swine flu cases on the wane, but state lab staying busy
Excessive Heat Warning, Heat Advisory in AR: Craighead , Crittenden , Cross , Lee , Mississippi , Phillips , Poinsett , St.Swine flu cases on the wane, but state lab staying busy.
|
|
|
Diabetes Is Significant Economic Burden For US Health-Care System
Excess medical expenses and reduced productivity due to diabetes costs the U.S.economy more than $174 billion annually, a figure that could be reduced by lifestyle modifications and preventive care and by pay-for-performance incentives...
|
|
|
Lip Cancer Information
What causes oral cancer?The main causes of oral cancer include: Tobacco use (90 percent of people with oral cancers use tobacco by smoking cigarettes, cigars, pipes, chewing tobacco and dipping snuff)? Alcohol use. Other causes of...
|
|
|
Diabetes is significant economic burden for US health-care system
Excess medical expenses and reduced productivity due to diabetes costs the U.S.economy more than $174 billion annually, a figure that could be reduced by lifestyle modifications and preventive care and by pay-for-performance incentives...
|
|
|
Diabetes is significant economic burden for US health-care system
xcess medical expenses and reduced productivity due to diabetes costs the U.S.economy more than $174 billion annually, a figure that could be reduced by lifestyle modifications and preventive care and by pay-for-performance incentives...
|
